Axiom Investors LLC DE Lowers Position in Insmed Incorporated (NASDAQ:INSM)

Axiom Investors LLC DE reduced its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 3.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 83,874 shares of the biopharmaceutical company's stock after selling 3,340 shares during the quarter. Axiom Investors LLC DE's holdings in Insmed were worth $5,791,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Insmed during the 4th quarter valued at about $126,606,000. Vanguard Group Inc. lifted its holdings in Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Insmed by 8.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock worth $215,842,000 after purchasing an additional 242,242 shares during the period. Principal Financial Group Inc. increased its stake in shares of Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after purchasing an additional 214,130 shares in the last quarter. Finally, TimesSquare Capital Management LLC raised its position in shares of Insmed by 41.4% during the 4th quarter. TimesSquare Capital Management LLC now owns 684,384 shares of the biopharmaceutical company's stock valued at $47,250,000 after purchasing an additional 200,515 shares during the period.

Remove Ads

Insmed Trading Down 4.6 %

INSM stock traded down $3.38 during mid-day trading on Friday, reaching $69.95. 876,015 shares of the stock traded hands, compared to its average volume of 2,226,685. The business has a 50-day moving average price of $77.97 and a two-hundred day moving average price of $73.99. The stock has a market capitalization of $12.66 billion, a PE ratio of -12.51 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on INSM shares. Wells Fargo & Company upped their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Bank of America increased their target price on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Stifel Nicolaus lowered their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. Truist Financial increased their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, Insmed has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Buying and Selling

In related news, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the sale, the insider now owns 101,549 shares in the company, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO William Lewis sold 8,218 shares of the company's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36. Following the completion of the transaction, the chief executive officer now owns 376,742 shares in the company, valued at $24,872,506.84. This represents a 2.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 532,207 shares of company stock valued at $41,683,028. Insiders own 4.60% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.